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http://dxObjectives: This study evaluated platelet function for an extended period of time in patients with a HeartMate II
continuous-flow left ventricular assist device (Thoratec Corporation, Pleasanton, Calif) with light transmission
aggregometry and investigated the potential role of this test in clinical management.
Methods: Twenty-four patients were studied prospectively after implantation. Mean duration of support was
8.5 months. Platelet functions were assessed with light transmission aggregometry induced by thrombin receptor
agonist peptide, ristocetin, or arachidonic acid. All patients received an aspirin regimen that was progressively
increased until arachidonic acid–triggered platelet aggregation dropped lower than 20%. Plasma levels of von
Willebrand factor were also determined when ristocetin-induced platelet agglutination was impaired.
Results: Intensity of platelet aggregation with thrombin receptor agonist peptide was little changed in patients
with a HeartMate II relative to control subjects. Aspirin dose greater than 160mg/d was progressively required in
46% of patients. Ristocetin-induced platelet agglutination was impaired in 4 patients in association with a lack
of high molecular weight vonWillebrand factor multimers. Three patients had thromboembolic events (12.5%)
and 8 (33%) suffered from major bleeding complications.
Conclusions: High platelet reactivity during treatment with aspirin is common in patients with a HeartMate II.
Moreover, light transmission aggregometry may detect impaired ristocetin-induced platelet agglutination,
enabling dosage of aspirin to be adjusted. Our strategy showed no major improvements in terms of thrombosis
rate when compared with published data, although bleeding frequency was somewhat reduced. Benefits of
light transmission aggregometry testing need to be assessed in a larger randomized study with a longer
follow-up. (J Thorac Cardiovasc Surg 2014;148:3119-25)See related commentary on pages 3125-6.Supplemental material is available online.he Laboratoire d’Hematologie,a CHU de Bordeaux, Pessac, France;
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MLeft ventricular assist devices (LVADs) are mechanical
blood pumps that are increasingly being used to treat severe
heart failure (eg, as a bridge to heart transplant, to allow
myocardial recovery, or as a long-term therapy). The
HeartMate II (Thoratec Corporation, Pleasanton, Calif) is
among the most commonly used LVAD systems.1-4
Among the associated risks, LVADs are still associated
with thromboembolic events, which remain at 5% to 15%
despite developments in device technology, anticoagulation
and antiplatelet strategies.5 Indeed, the ‘‘foreign’’ surfaces
of LVADs alter rheologic conditions, and blood stasis within
the chambers of the native heart can induce activation of
coagulation, which requires adequate anticoagulation to
prevent thromboembolic events.6 Because platelet function
is generally assumed to play a key role in these deleterious
complications, antiplatelet therapy is considered crucial
for such patients; anti–vitamin K anticoagulation is usually
given in association with at least 1 antiplatelet agent.5,7
In addition, thesepatients are exposed to increasedbleeding
tendencies causedbypossible impairedplatelet functionor ac-
quired vonWillebrand disease related to the high shear stress
induced by the device.8 Only a few studies have examined
platelet functions in patients with LVAD support.5 Hou€eldiovascular Surgery c Volume 148, Number 6 3119
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AA ¼ arachidonic acid
COX ¼ cyclooxygenase
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Mand colleagues9 studied the efficacy of aspirinwith light trans-
mission aggregometry (LTA) in 15 patients in whom an
external ventricular assist device had been implanted; howev-
er, these patients were only studied during a 6-week period af-
ter implantation. Our knowledge of platelet function in
patients with LVAD remains limited, and the long-term
follow-up of such patients has not been well described.Moni-
toring of platelet function may therefore be necessary to
manage an implanted LVAD to reduce thrombotic and
bleeding risks.
To that effect, the aim of this study was to test, with LTA,
whether the HeartMate II impaired platelet function, and to
investigate the possible role of LTA in the clinical manage-
ment of patients supported with the HeartMate II in the
early, intermediate, and late phases after implantation.MATERIALS AND METHODS
Inclusion of Patients
Patients who underwent implantation of a HeartMate II and who had
given their consent were enrolled in this observational study between April
2011 and June 2013. Clinical data were obtained from the patients’ medical
records. During follow-up visits, patients were systematically assessed for
symptoms of bleeding or thromboembolism, and any other concerns or
complications related to their devices were noted and investigated.
Control patients were healthy subjects whowere not receiving any drugs
that might impair platelet function.
This observational study was approved by our institutional review
board (Comite de Protection des Personnes Sud-Ouest et Outre Mer III,
Bordeaux, France).
Testing Platelet Function With LTA
Platelet-rich plasma was obtained by centrifugation of 0.129-mol/L
(3.8%) citrated blood tubes (BD Vacutainer; Becton, Dickinson and Com-
pany, Franklin Lakes, NJ) at 1100 rpm for 10 minutes. LTAwas performed
without adjusting the platelet count with 0.5-mg/mL arachidonic acid (AA;
Nu Chek Prep, Elysian, Minn), 1.5-mg/mL ristocetin (Diagnostica Stago,
Asnieres sur Seine, France) and with 50-mmol/L thrombin receptor acti-
vating peptide (TRAP; Neosystem SA, Strasbourg, France) with an
APACT 4004 aggregometer (Elitech, Salon de Provence, France). TRAP
is a synthetic peptide that mimics the effects of thrombin on platelets; it al-
lows activation of protease-activated receptors, leading to platelet aggrega-
tion. It is a strong platelet agonist, and an abnormal response to high
concentrations of TRAP may reflect severely impaired platelet function.
Moreover, at high concentrations of TRAP, protease-activated receptor
pathways are not affected by aspirin intake, thus reflecting approximate
platelet baseline reactivity. Maximal intensity was recorded for 10 minutes
and expressed as percentage change in transmittance.3120 The Journal of Thoracic and Cardiovascular SurAntiplatelet Therapy and Anticoagulation Protocol
for HeartMate II
Anti–vitamin K therapy (fluindione) was started when postoperative
bleeding was acceptable, typically on day 2 after surgery, to maintain the
international normalized ratio (INR) between 2 and 3.
Parenteral aspirin therapy was switched to oral therapy when oral
feeding became possible. Aspirin therapy, at a daily dose of 75 to
100 mg, was administered for 24 to 48 hours after device placement,
when basal platelet function was considered almost normal and there
was an absence of related bleeding. When possible, patients were tested
weekly while in the hospital (early phase,<1 month, and intermediate
phase, 1-3 months). After discharge, patients attended monthly follow-up
visits at the study center’s clinic (late phase,>3 months).
The aspirin regimen was progressively increased (160mg/d to 300mg/d
to 500 mg/d) until AA-triggered platelet aggregation dropped below 20%.
Biologic aspirin resistance was defined by any persistent ex vivo platelet
aggregation greater than 20% induced by AA, independent of the daily
dose of aspirin used.10
von Willebrand Factor Studies
When ristocetin-induced platelet agglutination was impaired,
complementary von Willebrand factor (vWF) studies were performed.
The PFA-100 point-of-care assay (Siemens, Marburg, Germany) assessed
platelet function in whole blood under conditions of high shear stress. Stan-
dard collagen/epinephrine or collagen/adenosine diphosphate cartridges
were used. Aspirin treatment usually prolongs collagen/epinephrine
closure time but not collagen/adenosine diphosphate closure time. The
plasma antigen vWF was measured with the LIATEST vWF:Ag kit (Diag-
nostica Stago), and vWF ristocetin-cofactor activity was measured with re-
agents from Helena Biosciences Europe (Helena Biosciences Europe,
Gateshead, UK). Multimeric patterns of vWF were determined by low-
resolution gel electrophoresis (1.2% sodium dodecylsulfate agarose) in a
Multiphor II Electrophoresis system (GE Healthcare Life Sciences, Piscat-
away, NJ) and visualized with peroxidase-conjugated anti–vWF IgG anti-
bodies (DAKO, Glostrup, Denmark). High-molecular-weight multimer
profiles were compared with those of normal human plasma.
Statistical Analyses
Data are expressed as mean  SD for normally distributed continuous
variables, as median with interquartile range for nonnormally distributed
continuous variables, and as number and percentage of patients for
categoric data. The normal distribution of continuous variables was
assessed with skewness and kurtosis statistical tests. A Mann-Whitney
U test was conducted to compare median values. Statistical analyses were
performed with the SPSS statistical software package (IBM, Armonk NY).
RESULTS
Patients Characteristics
We prospectively enrolled 24 patients during the study
period. Only 3 patients were female. The overall median
age was 57  12 years. Eleven of the patients underwent
LVAD placement under emergency conditions. All charac-
teristics of the patients are summarized in Table 1.
Impact of HeartMate II Treatment on Platelet
Function
Our aim was to investigate whether implantation of a
HeartMate II was associated with severely impaired platelet
function. In the early, intermediate, or late phase after
LVAD implantation, values of TRAP-induced platelet
aggregation showed that basal platelet function was only
slightly diminished relative to normal control valuesgery c December 2014
TABLE 1. Characteristics of included patients (n ¼ 24)
Sex (male/female ratio) 21:3
Age (y) 57  12
Underlying heart disease
Ischemic heart failure 21
Dilated cardiomyopathy 3
LVAD placement
Under emergency conditions 11
Scheduled for surgery 13
ICU stay (d) 12 (7-16)
Hospital stay (d) 59 (41-68)
Duration of follow-up (mo) 7 (2-13)
Data are expressed as number and percentage of patients (%), mean SD, or median
with interquartile range. LVAD, Left ventricular assist device; ICU, intensive care unit.
Fiore et al Perioperative Management(mean D TRAP values of 11% and 7%, respectively, at 1
and 6 months), suggesting an absence of severely impaired
platelets in our patients (Figure 1).
Patients were also closely monitored with LTA to
optimize the dosage of aspirin. With a cutoff value of a
20% LTA response to AA, an aspirin dose greater than
75 mg/d was progressively required by 92% (22 of 24) ofFIGURE 1. A, Platelet aggregation induced by thrombin receptor activating
Numbers above bars represent P values. B, Function additionally broken down b
of maximal platelet aggregation in 30 healthy subjects.
The Journal of Thoracic and Carpatients, and a dose greater than 160 mg/d was required
by 46% (11 of 24) (Table 2). In some patients, aspirin resis-
tancewas observed at several months after HeartMate II im-
plantation, suggesting that this condition may persist
throughout LVAD support (Figure E1).
Ristocetin-induced platelet agglutination was impaired in 4
of the 24 patients (Figure 2, A). Collagen/epinephrine closure
time and collagen/adenosine diphosphate closure time were
significantly prolonged in 3patients (Table 3).Averageplasma
concentrations of vWFprotein, vWFcofactor activity and fac-
torVIII:Cwere elevated in all 4 patients,which suggests an in-
flammatory condition induced by the device (Table 3). AvWF
multimeric analysis was therefore performed, even though
laboratory vWF values were normal; this showed a lack of
high-molecular-weight multimers and confirmed an acquired
von Willebrand disorder in these patients (Figure 2, B).Adverse Events Associated With Defects in Platelet
Function
The mean INR for all patients during support was 2.03
0.45. Because the aspirin dose regimen was progressivelypeptide (50 mmol/L) during left ventricular assist device (LVAD) support.
y aspirin dosing. The dashed red line corresponds to the average percentage
diovascular Surgery c Volume 148, Number 6 3121
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TABLE 2. Effect of aspirin on platelet inhibition in the 24 patients
with a HeartMate II
Response to aspirin AS AR
Total patients 20 (83%) 4 (17%)
Aspirin dose (mg/d)
75-100 2 (8.3%) 2 (8.3%)
160 9 (37.5%) 1 (4.2%)
300 8 (33.3%) 1 (4.2%)
500 1 (4.2%) 0 (0%)
Data are expressed as numbers and percentages of patients. AS, Aspirin sensitivity;
AR, aspirin resistance.
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Mincreased, we were specifically interested in the occurrence
of major bleeding events that occurred a long time after
surgery. According to this study, 8 patients (33%) had a
major bleeding complication; these were an intracerebral
hemorrhage, psoas muscle hematoma, and gastrointestinal
bleeding from colonic lesion or cecal angiodysplasia.
Among these patients, only 3 required an aspirin dose of
300 mg/d, whereas the others received 75 to 160 mg/d.
Two of the patients who received 300 mg/d also had
impaired ristocetin-induced platelet agglutination and a
lack of high-molecular-weight vWF multimers, which
probably increased their risk of bleeding. Finally, INR
remained within normal limits in 6 of the 8 patients with
bleeding events.
Only 3 patients (12.5%) had thromboembolic events,
corresponding to pump thrombosis or ischemic stroke.
Notably, these complications were not associated with
biologic aspirin resistance or hypoanticoagulation. Indeed,
in all cases, INRs at the time of the clotting even were
within expected values (between 2 and 3).
DISCUSSION
In recent years, the use of mechanical circulatory support
as a bridge to transplant has become a reliable and safeFIGURE 2. A, Platelet agglutination induced by ristocetin (1.5 mg/mL), showi
to the control value (C). B, Western blot analysis of von Willebrand factor show
control subject (C).
3122 The Journal of Thoracic and Cardiovascular Surtreatment modality because of the significant gain in
clinical experience.11 However, despite meticulous efforts
to manage anticoagulation and antiplatelet therapy, throm-
boembolic events still may occur, and reduced platelet
function can be an important risk factor for increased
bleeding.12 Our study focused on platelet function in
patients with a HeartMate II implant. Our major findings
are that (1) most of the patients with HeartMate II implants
required high doses of aspirin to reduce maximum
AA-induced platelet aggregation and (2) a data-based
approach to modulating aspirin dose did reduce the
bleeding relative to rates usually reported at comparable
dose levels of aspirin.
Indeed, we used LTA to optimize the dose of aspirin in
patients with HeartMate II implants and showed that a small
proportion of them were sensitive to a dose of 75 mg/d,
which reduced the maximum AA-induced platelet
aggregation to less than 20%. In outpatients with stable
coronary artery disease, aspirin efficacy has been observed
at low doses, but with some individual variability.13 With a
cutoff of value of a 20% LTA response to AA, Blann and
associates14 showed that more than 67% of 175 patients
with stable coronary artery disease were aspirin sensitive
at a dose of 75 mg/d.14 We found that biologic aspirin
hyporesponsiveness is common in patients after Heart
Mate II implantation, even in the intermediate and late
phases. This finding is in agreement with a previous report,
which showed a resistance to aspirin in 26% of the patients
despite 250-mg/d aspirin treatment. However, those pa-
tients were only studied during a 6-week period after im-
plantation, whereas the mean follow-up period of our
study was 8.5 months.9
A prolonged inflammatory reaction is observed in
patients who have an implanted LVAD15,16; enhanced
regeneration of new platelets in response to stress andng a diminished response in a patient (P) with HeartMate II support relative
ing a loss of high-molecular-weight multimers in a patient (P) relative to a
gery c December 2014
TABLE 3. Laboratory values for von Willebrand factors, platelet counts, and closure times of the 4 patients with a HeartMate II and impaired
ristocetin-induced platelet agglutination
Patient
vWF:Ag
(%, 50-150)
vWF:RCo
(%, 50-150) FVIII (%, 50-150) RCo/RAg ratio Platelets (109 cells/L) CEPI-CT (s) CADP-CT (s)
1 138 113 97 1.2 133 — —
2 212 130 284 0.6 541 >300 297
3 296 >240 233 >0.8 170 >277 200
4 283 178 230 0.8 222 >300 >300
vWF:Ag, Plasma von Willebrand factor antigen; vWF:RCo, plasma von Willebrand factor ristocetin cofactor activity; RCo/RAg ratio, ratio of cofactor to antigenic protein in
plasma; CEPI-CT, collagen/epinephrine closure time; CADP-CT, collagen/adenosine diphosphate closure time.
Fiore et al Perioperative Managementinflammation could explain the resistance to aspirin in these
patients.17-19 Indeed, the entry of new platelets containing
active cyclooxygenase (COX) into circulation may
counteract the complete and persistent suppression of
thromboxane biosynthesis by aspirin.20 It is also known
that platelet thromboxane formation principally depends
on COX-1, the constitutive isoform of COX.21 Neverthe-
less, careful analysis of COX isoforms in platelets have
also revealed a small amount of the inducible isoform
COX-2, which is 170-fold less sensitive to inhibition by
aspirin.22,23 A study has demonstrated that an increased
platelet turnover elevated platelet COX-2, and it has been
speculated that platelet resistance to aspirin may be induced
by COX-2 generating critical amounts of thromboxane.24
All these observations may suggest that aspirin resistance
in patients with LVADs can be overcome by the administra-
tion of higher doses, as we observed in our study. In 4 cases,
however, impaired platelet inhibition was averted by
administering aspirin twice daily, thereby reversing a
shorter lasting effect of aspirin related to the faster renewal
of platelets. One of our patients had aspirin dose adjusted toFIGURE 3. Clinical algorithm and proposals to use light transmission aggre
(HMII). VWF, von Willebrand factor.
The Journal of Thoracic and Car75 mg twice daily, rather than 160 mg once daily, and 3
others had the dose adjusted to 160 mg twice daily rather
than 300 mg once daily. The reduction of thromboxane B2
levels related to an increased aspirin dose could support
this hypothesis. Nonetheless, whether these patients are
less sensitive to the effects of aspirin still remains to be
defined and needs to be further explored. Other studies in
larger patient populations are necessary to identify new
and specific markers of aspirin resistance in such patients.
We also examined whether ristocetin-induced platelet
agglutination defects were caused by vWF abnormalities.
HeartMate II appears to induce an acquired vWF disease
similar to that previously observed in patients with aortic
stenosis or other cardiac defects.25-29 Uriel and
colleagues26 measured high-molecular-weight vWF
multimers in 31 patients with HeartMate II support and
showed that these multimers were reduced in all
patients, yet only 18 of the 31 (58%) patients had a bleeding
episode. In our study, only 4 patients (17%) had impaired
ristocetin-induced platelet agglutination associated with a
lack of high-molecular-weight vWF multimers. This resultgometry (LTA), to manage the treatment of patients with a HeartMate II
diovascular Surgery c Volume 148, Number 6 3123
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Msuggests that LTA is not sensitive enough to detect
abnormalities of vWF in patients with LVAD support.
Nonetheless, in 3 of these 4 cases, impaired ristocetin-
induced platelet agglutination was associated with a
major bleeding event. The etiology of bleeding events in
patients treated with the HeartMate II is multifactorial,
and the LTA test may suggest a specific cause. Finally,
LTA enabled us to adapt and reduce aspirin dose for these
patients.
Previous studies have shown that thromboembolic events
in patients with LVAD support occur in 5% to 15% of
cases, whereas bleeding events are reported in 30% to
50% of cases.5,30 In contrast to the approaches used in
previous studies, we made adjustments to aspirin dosage
for a long period after HeartMate II implantation to
improve long-term outcomes. In our study, 3 patients
(12.5%) had some thromboembolic event, and 8 (33%)
had a major bleeding complication. Thus, in this particular
population, LTA monitoring with adjustment of aspirin
therapy did not significantly improve the rate of thromboses
relative to other published data; however, bleeding
frequency was somewhat reduced. LTA testing with
adjustment of aspirin dose had no impact on other
prognostic factors, such as adherence to treatment,
procedure-related technical factors, or other coexisting
conditions. We cannot, however, exclude the possibility of
greater benefits of LTA testing in a larger randomized
study with a prolonged follow-up. Moreover, our patient
recruitment varied somewhat from previously published
data on patients with HeartMate II support, which reported
that 20% of patients were female, and sex bias may be
associated with potential significant confounding variables.
Finally, on the basis of our results, we can propose a clin-
ical algorithm that uses LTA, to manage patients with a
HeartMate II (Figure 3). Low-dose aspirin therapy may be
administered for 24 to 48 hours after device placement,
when basal platelet functions are considered almost normal.
The aspirin regimen is then progressively increased until
AA-triggered platelet aggregation drops below 20%. If
LTA detects impaired ristocetin-induced platelet agglutina-
tions, then vWF studies are performed to evaluate vWF
level, function, and multimeric distribution. Anticoagulant
or platelet antiaggregating agents are then adjusted
according to the clinical situation and laboratory test
results.
In conclusion, we have successfully used LTA to test
platelet function and to optimize the dose of aspirin for 24
patients supported with the HeartMate II. Further studies
are required, however, to establish the role of LTA as a guide
to monitor aspirin dosage in this clinical setting.
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Services) for reviewing the manuscript.
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MFiore and colleagues1 report variability in the effectiveness
of aspirin as a platelet-inhibitor measured by light-
transmission aggregometry in patients after HeartMate II
(Thoratec Corp, Pleasanton, Calif) ventricular-assist device
(VAD) implantation. Like many centers performing VAD
surgery, the investigators used a vitamin K pathway inhibi-
tor to achieve an international normalized ratio of 2 to 3
along with oral aspirin to prevent thromboembolism. The
clinical issue this study addresses is the value of platelet
light-transmission aggregometry (LTA) for assessing the
effectiveness of platelet inhibition by aspirin in patients
with an axial VAD and reflects a long-standing need.2
Resistance to aspirin and anticoagulation management in
patients with VAD are unresolved issues open to differing
interpretation.3 Several factors drive local anticoagulation
practices, including device type, pump flow, coagulation
measurements used, and past experience. Tailoring anticoa-
gulation to individual patients relies on having a measure
or measures of anticoagulant effectiveness that are highlyassociated with important patient outcomes. The clinical
problem is complicated by uncertainty regarding which ther-
apeutic targets to use to measure the multifaceted compo-
nents of the coagulation cascade in patients with VAD.4 It
is further complicated by temporal variation in coagulation
status, from immediate postoperative coagulopathy to the
procoagulant environment that is a nearly universal response
to VAD placement, in part from VAD-induced loss of high-
molecular-weight von Willebrand factor multimers.5 Indi-
vidual variability in aspirin responsiveness, anticoagulant
drug metabolism, circulating levels of coagulation factors,
platelet count and fibrinolytic activity, and etiologic cardiac
disease is seen in patients with a VAD and in cardiac popu-
lations and determines coagulation status and response to
anticoagulants and antiplatelet agents.6,7 This variation
predicts a failure of 1-size-fits-all anticoagulation strategies
and drives the need for research such as this study to nail
down this issue. Further, there is no proven advantage to
steering either an anticoagulant or a procoagulant
course—both are bad. Embolic stroke is an event feared
by patients more than death and the physician response to
bleeding is often to reduce the level of anticoagulation,
resulting in a greater incidence of embolic events.8
This study has potential value for its reliance upon LTA to
determine an appropriate long-term aspirin dosing in their
patients over a period of more than 8 months but is limited
by the small cohort size. The study observations of wide vari-
ability in aspirin dose required to achieve platelet inhibition
measured by LTA, and that the majority of patients required
aspirin doses several times higher than those required to
achieve platelet inhibition in ambulatory coronary artery dis-
ease2 are valuable. Although the authors state that adjustment
of aspirin dosing according to LTA reduced the rate ofdiovascular Surgery c Volume 148, Number 6 3125
FIGURE E1. Platelet aggregation testing in the presence of arachidonic acid (0.5 mg/mL). Resistance to aspirin treatment (R) was defined as persisting
platelet aggregation greater than 20% despite daily administration of aspirin. S, Aspirin sensitivity; LVAD, left ventricular assist device.
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